^
Association details:
| Biomarker: | MET overexpression + KDR overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial
Published date:
02/11/2022
Excerpt:
...data showed that patients with c-MET/VEGFR-2 HIGH tumours treated with bevacizumab had significantly reduced OS compared to c-MET/VEGFR-2 LOW tumours (39.3 vs. > 60 months; multivariable HR 2.00, 95%CI 1.08–3.72, P = 0.03; Fig. 1A)...In conclusion, in bevacizumab-treated patients diagnosed with EOC, high c-MET/VEGFR-2 co-localisation on tumour tissue and the VEGFR-2 rs2305945 G/G variant, which may be biologically related, was associated with worse survival outcomes.
DOI:
10.1186/s12916-022-02270-y
Trial ID:
